The lawsuit says Gavalas started using Gemini in August 2025 for common uses like shopping, writing support, and travel planning. It then notes Gavalas started to use the technology more frequently, and that its tone shifted with time, allegedly convincing him it was impacting real-world outcomes. Gavalas took his life on Oct. 2, 2025.
Before PDUFA was passed, the drug approval process was notoriously slow. The average drug would take between 21 and 29 months to be reviewed. Now, the FDA’s target is between six to 10 months.
。关于这个话题，快连下载提供了深入分析
���[���}�K�W���̂��m�点
GrapheneOS Foundation Partnership